In vitro interaction of micafungin and fluconazole against Candida [12]

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 188-190

  Rodríguez, M Mar ^a   Ruiz, Mery ^a   Pastor, F Javier ^a   Quindos G ^b   Carrillo, A ^c   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Asesoria Cientifica y de Investigacion Aplicada   (Spain)

Author keywords

Antifungal drugs; Azoles; Echinocandins

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS ISOLATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG SYNERGISM; FLUCONAZOLE; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 34447554523     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm177     Document Type: Letter

References (11)

1. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-61.
2. Roling EE, Klepser ME, Wasson A et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-7.
3. Serena C, Fernández-Torres B, Pastor FJ et al. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 2005; 49: 2994-6.
4. Serena C, Marine M, Pastor FJ et al. In vitro interaction of mica-fungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 2005; 55: 1020-3.
5. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
6. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
7. Laverdiere M, Hoban D, Restieri C et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50: 119-23.
8. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
9. Karlowsky JA, Hoban DJ, Zhanel GG et al. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006; 27: 174-7.
10. Marine M, Serena C, Pastor FJ et al. Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother 2006; 58: 1295-8.
11. Serena C, Pastor FJ, Gilgado F et al. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother 2005; 49: 497-502.